(FOMX) - Earnings & Price History

FOMX: - 6.06, $227.92M, -0.05 (-0.82%)

Sector: Healthcare - Industry: Biotechnology

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne and other skin conditions in the United States, Germany, France, and Israel. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by methicillin-resistant staphylococcus aureus. The company is also developing FMX103, a version of its minocycline foam FMX101, which is in Phase II clinical trial for the treatment of rosacea; and FDX104 that has completed Phase II clinical trail for the treatment of chemotherapy-induced rash. It has development and license ag

Past FOMX reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-02-21AMC-0.269.6210.12109.3410.22-1.19%-3.80%-4.94%254.21K
2016-08-10BMO-0.258.168.147.617.568.38-6.51%7.23%0.25%159.10K
2016-05-10BMO-0.236.66.416.496.417.121.25%1.69%2.96%252.89K
2016-03-03BMO-0.215.96.056.045.736.28-0.17%-2.32%-2.48%61.51K
2015-11-11BMO-0.196.726.966.986.447.010.29%▲-3.72%-3.45%139.80K
2015-08-209.799.829.339.0110.1-4.99%4.93%-0.31%218.59K
2015-05-12AMC-0.1811.2510.2310.4311.499.97%377.08K
2015-03-18BMO-0.059.6310.19.899.0710.08-2.08%-2.63%-4.65%642.38K
2014-11-17BMOFoamix Pharma-0.07-0.125.35.385.55.285.52.23%▲-3.64%-1.49%60.40K

Login | Register
Friday Nov 16, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades